2024-512019-36-00RecruitingPhase 1
A first-in-human clinical study to assess safety and tolerability of genetically modified T-cells in ROR1 positive tumors
Source: EU CTIS (euclinicaltrials.eu) · Last updated 13 Apr 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- First submitted
- 11 Jun 2024
- Start date
- 9 Apr 2025
- Lead sponsor
- Universitaetsklinikum Wuerzburg AöR
- EU CT number
- 2024-512019-36-00
- EudraCT number
- 2022-003728-41
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 44
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Universitaetsmedizin Berlin KöR | Berlin | Germany | Recruiting |
| Universitaetsklinikum Koeln AöR | Cologne | Germany | Recruiting |
| Universitaetsklinikum Wuerzburg AöR | Wuerzburg | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.